Scott Boiko

958 total citations
13 papers, 289 citations indexed

About

Scott Boiko is a scholar working on Oncology, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Scott Boiko has authored 13 papers receiving a total of 289 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 7 papers in Molecular Biology and 4 papers in Pathology and Forensic Medicine. Recurrent topics in Scott Boiko's work include Cancer-related Molecular Pathways (5 papers), RNA modifications and cancer (2 papers) and Cancer Research and Treatments (2 papers). Scott Boiko is often cited by papers focused on Cancer-related Molecular Pathways (5 papers), RNA modifications and cancer (2 papers) and Cancer Research and Treatments (2 papers). Scott Boiko collaborates with scholars based in United States, Australia and Italy. Scott Boiko's co-authors include A.I. Yashin, Qihua Tan, E Feraco, Serena Dato, Vincenzo Mari, Cristiana Barbi, Giuseppina Rose, Valentina Greco, G. De Benedictis and Claudio Franceschi and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Scott Boiko

11 papers receiving 280 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Scott Boiko United States	5	157	133	116	75	50	13	289
Yosi Gozlan Israel	7	181 1.2×	147 1.1×	110 0.9×	72 1.0×	35 0.7×	11	356
Hanna Artsi Israel	6	137 0.9×	77 0.6×	167 1.4×	47 0.6×	4 0.1×	7	301
Jay W. Yang China	6	119 0.8×	60 0.5×	210 1.8×	93 1.2×	4 0.1×	9	338
Sini Pirnes-Karhu Finland	7	28 0.2×	55 0.4×	117 1.0×	30 0.4×	4 0.1×	10	232
Rachel S. Fletcher United Kingdom	7	92 0.6×	58 0.4×	48 0.4×	31 0.4×	4 0.1×	7	182
Jacob Rose United States	12	20 0.1×	46 0.3×	136 1.2×	36 0.5×	8 0.2×	28	259
Erika Fiorino Italy	9	37 0.2×	108 0.8×	137 1.2×	70 0.9×	1 0.0×	15	330
Nadja Gebert Germany	7	10 0.1×	88 0.7×	140 1.2×	35 0.5×	40 0.8×	9	287
Jonathan Kato United States	4	9 0.1×	198 1.5×	140 1.2×	22 0.3×	57 1.1×	7	340
Xurde M. Caravia Spain	10	4 0.0×	84 0.6×	244 2.1×	46 0.6×	41 0.8×	15	366

Countries citing papers authored by Scott Boiko

Since Specialization

Citations

This map shows the geographic impact of Scott Boiko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott Boiko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott Boiko more than expected).

Fields of papers citing papers by Scott Boiko

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott Boiko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott Boiko. The network helps show where Scott Boiko may publish in the future.

Co-authorship network of co-authors of Scott Boiko

This figure shows the co-authorship network connecting the top 25 collaborators of Scott Boiko. A scholar is included among the top collaborators of Scott Boiko based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott Boiko. Scott Boiko is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Ciccone, David, Scott Boiko, Samantha Carreiro, et al.. (2025). Highly selective HPK1 inhibitor NDI-101150 mediates immune cell activation and robust antitumor responses, distinct from immune checkpoint blockade. Journal for ImmunoTherapy of Cancer. 13(7). e012064–e012064.

Svensson, Robert, Scott Boiko, Beth Browning, et al.. (2025). Abstract 2894: NTX-452: a non-covalent, potent, selective and highly efficacious WRN inhibitor with best-in-class potential for the treatment of MSI-H tumors. Cancer Research. 85(8_Supplement_1). 2894–2894. 2 indexed citations

Noel, Marcus Smith, Bhaskar Srivastava, Scott R. Daigle, et al.. (2024). Phase 1/2 trial of the HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab: Clinical update.. Journal of Clinical Oncology. 42(16_suppl). 3083–3083. 6 indexed citations

Ciccone, David, Scott Boiko, Scott R. Daigle, et al.. (2023). 1340 NDI-101150 is a potent and highly selective hematopoietic progenitor kinase 1 (HPK1) inhibitor that promotes a robust and broad anti-tumor immune response. SHILAP Revista de lepidopterología. A1494–A1494. 1 indexed citations

Sommerhalder, David, Marcus Smith Noel, Scott Boiko, et al.. (2023). 751 Monotherapy results from an ongoing phase 1a dose escalation study of NDI-101150, a highly selective oral hematopoietic progenitor kinase 1 (HPK1) inhibitor. SHILAP Revista de lepidopterología. A847–A847. 3 indexed citations

Barlaam, Bernard, Scott Boiko, Scott Boyd, et al.. (2020). Novel potent and selective pyrazolylpyrimidine-based SYK inhibitors. Bioorganic & Medicinal Chemistry Letters. 30(22). 127523–127523. 3 indexed citations

Boiko, Scott, Theresa A. Proia, Maryann San Martin, et al.. (2020). Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas. Blood. 137(21). 2947–2957. 19 indexed citations

Boiko, Scott, Theresa A. Proia, Maryann San Martin, et al.. (2019). Abstract 2500: Transient CDK9 inhibition with AZD4573 modulates Bfl-1 in preclinical lymphoma models. Cancer Research. 79(13_Supplement). 2500–2500. 1 indexed citations

Boiko, Scott, Theresa A. Proia, Maryann San Martin, et al.. (2018). Abstract 306: A mechanistic rationale for combining acalabrutinib with CDK9 inhibitor, AZD4573, in ABC-DLBCL. Cancer Research. 78(13_Supplement). 306–306. 4 indexed citations

10.

Cidado, Justin, Theresa A. Proia, Scott Boiko, et al.. (2018). Abstract 310: AZD4573, a novel CDK9 inhibitor, rapidly induces cell death in hematological tumor models through depletion of Mcl1. Cancer Research. 78(13_Supplement). 310–310. 10 indexed citations

11.

Cidado, Justin, Theresa A. Proia, Gareth P. Gregory, et al.. (2017). Abstract 4295: AZ’5576, a selective CDK9 inhibitor, demonstrates in vitro and in vivo activity in diverse preclinical models of non-Hodgkin lymphoma. Cancer Research. 77(13_Supplement). 4295–4295. 1 indexed citations

12.

Cidado, Justin, Minhui Shen, Michael Grondine, et al.. (2016). Abstract 3572: AZ5576, a novel potent and selective CDK9 inhibitor, induces rapid cell death and achieves efficacy in multiple preclinical hematological models. Cancer Research. 76(14_Supplement). 3572–3572. 3 indexed citations

13.

Rose, Giuseppina, Serena Dato, Dina Bellizzi, et al.. (2003). Variability of the SIRT3 gene, human silent information regulator Sir2 homologue, and survivorship in the elderly. Experimental Gerontology. 38(10). 1065–1070. 236 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact